Clinical trial · Interventional

EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas

An Open-label, Multicenter, Exploratory Clinical Study of the EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas.

NCT07339527CI-TRIAL-00100807not yet recruitingPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

This is a prospective, multicenter, open-label, phase Ib/II clinical study to evaluate the safety and efficacy of EZH2 inhibitor Zeprumetostat in combination therapy for patients with relapsed or refractory mature T-cell and NK-cell lymphomas.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Mature T-cell and NK-cell Lymphoma	Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma	ALIAS	0.90

Interventions

Interventions (3)

Intervention	Type	Mapped drug	Match
Chidamide	Drug	—	UNRESOLVED
Golidocitinib	Drug	—	UNRESOLVED
Zeprumetostat	Drug	—	UNRESOLVED

Design

Arms and outcomes

Arms (1)

type
EXPERIMENTAL
label
Zeprumetostat Combined with Golidocitinib or Chidamide
description
In Cohort 1, patients will receive Zeprumetostat in combination with Golidocitinib, with an initial dose of 350mg of Zeprumetostat. Each treatment cycle is 28 days. The Zeprumetostat will be combined with Golidocitinib at the RP2D dose level for an extension study. In Cohort 2, patients will receive Zeprumetostat in combination with Chidamide, with an initial dose of 350mg of Zeprumetostat. Each treatment cycle is 28 days. The Zeprumetostat will be combined with Chidamide at the RP2D dose level for an extension study.
interventionNames
1. Drug: Zeprumetostat
2. Drug: Golidocitinib
3. Drug: Chidamide

Primary outcomes (3)

measure
DLT for Phase 1b
timeFrame
The first cycle after administration (each cycle is 28 days)
description
To identify the dose-limiting toxicity
measure

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years

Show eligibility criteria text

Inclusion Criteria:

* Voluntarily participate in the clinical study; fully understand and be informed about the study and sign the Informed Consent Form (ICF); willing to comply with and capable of completing all trial procedures;
* Age ≥ 18 years
* Pathologically confirmed mature T-cell and NK-cell lymphomas.
* Using the Lugano 2014 criteria, the patient must have at least one measurable or evaluable lesion
* Participants must have experienced disease progression, treatment failure, or intolerance following standard therapy. Patients with ALCL are required to have previously received anti-CD30-targeted therapy, while patients with NKTCL must have previously been treated with pegaspargase or L-asparaginase.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
* Adequate organ and bone marrow function

Exclusion Criteria:

* Lymphoma involvement in the central nervous system or meninges
* Active infections
* Prior treatment with an EZH2 inhibitor or an EZH1/2 dual inhibitor that was discontinued due to intolerance to toxicity;
* For patients enrolled in Cohort 1, prior treatment with a JAK inhibitor that was discontinued due to intolerance to toxicity;
* For patients enrolled in Cohort 2, prior treatment with an HDAC inhibitor that was discontinued due to intolerance to toxicity.
* History of Human Immunodeficiency Virus (HIV) infection and/or Acquired Immunodeficiency Syndrome (AIDS).
* Patients with mental disorders or those unable to provide informed consent
* Any other condition deemed by the investigator to be unsuitable for study enrollment;
* Pregnant or breastfeeding women, and subjects of childbearing potential who are unwilling to use contraception;
* Individuals with a known hypersensitivity to any of the investigational drugs.

References

Publications (0)

Data not yet available

No reference posted for this study.